AbbVie is a pharmaceutical company that develops and sells prescription drugs, primarily in immunology, oncology, and aesthetics. Its top products include Skyrizi and Rinvoq (autoimmune conditions), Imbruvica and Venclexta (blood cancers), and Botox (both cosmetic and therapeutic uses). Customers are patients, but revenue flows through hospitals, specialty pharmacies, and insurers. The company makes money by selling branded drugs at patent-protected prices, with ongoing R&D and acquisitions used to expand and refresh the product lineup as older drugs like Humira face biosimilar competition.
Employees57,000IPODec 10, 2012SIC5122HQ1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
71.5%
Operating Margin
33.9%
EBITDA Margin
30.3%
Net Margin
9.8%
OCF Margin
30.3%
FCF Margin
28.3%
Returns on Capital
ROE
—
ROA
4.7%
ROIC
14.1%
ROCE
12.4%
ROC (Greenblatt)
208.3%
3Y ROIIC
355.4%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
80.63
Forward P/E
20.37
P/E ex-NRI
26.26
Shiller P/E (CAPE)
59.22
Cash Flow Multiples
P/FCF
27.80
P/OCF
25.92
P/Owner Earnings
53.98
FCF Yield
3.61%
Enterprise Value Multiples
EV / EBIT
48.96
EV / Forward EBIT
22.39
EV / EBITDA
29.19
EV / Forward EBITDA
17.59
EV / Revenue
8.84
EV / Forward Revenue
8.45
Asset / Sales
P/S
7.86
P/B
—
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.37%
Forward Dividend Yield
2.41%
3Y Dividend Growth
5.2%
Payout Ratio
0.62
5Y Yield on Cost
3.73%
Buybacks & Dilution
3Y Buyback Ratio
0.00%
Combined
Shareholder Yield
2.56%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
−11.93
Gross Debt / EBITDA
3.64
Cash / Debt
0.09
Equity / Assets
−0.04
Coverage
Interest Coverage
7.49
Short-Term Liquidity
Current Ratio
0.81
Quick Ratio
0.69
Cash Ratio
0.16
Composite Scores
Piotroski F-Score
8
Altman Z-Score
2.40
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-07-15
$1.73
2026-08-14
2026-04-15
$1.73
2026-05-15
2026-01-16
$1.73
2026-02-17
2025-10-15
$1.64
2025-11-14
2025-07-15
$1.64
2025-08-15
2025-04-15
$1.64
2025-05-15
2025-01-15
$1.64
2025-02-14
2024-10-15
$1.55
2024-11-15
2024-07-15
$1.55
2024-08-15
2024-04-12
$1.55
2024-05-15
10 of 55
View allDate
Transcript
Type
2026-07-31
Q2 2026 Abbvie Inc Earnings Call Transcript
Earnings Call
2026-06-22
Abbvie Inc to Acquire Apogee Therapeutics Call Transcript
Company Actions
2026-06-09
AbbVie Inc at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-04-29
Q1 2026 AbbVie Inc Earnings Call Transcript
Earnings Call
2026-03-10
AbbVie Inc at Leerink Global Healthcare Conference Transcript
Conference Presentations
2026-03-03
AbbVie Inc at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-04
Q4 2025 AbbVie Inc Earnings Call Transcript
Earnings Call
2026-01-14
AbbVie Inc at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-03
AbbVie Inc at Piper Sandler Healthcare Conference Transcript
Conference Presentations
2025-10-31
Q3 2025 AbbVie Inc Earnings Call Transcript
Earnings Call
10 of 89
5-Step DuPont Analysis
ROE %
-206.28%
×
×
Net Margin %
9.80%
×
×
Operating Margin %
33.94%
Operating Income
$21.85B
÷
Revenue
$64.39B
×
Tax Burden
0.7254
Net Income
$6.31B
÷
Pretax Income
$8.70B
×
Interest Burden
0.3981
Pretax Income
$8.70B
÷
Operating Income
$21.85B
×
Asset Turnover
0.47
÷
Revenue
$64.39B
÷
Average Total Assets
$136.15B
Begin Total Assets
$137.18B
End Total Assets
$135.12B
×
Equity Multiplier
-44.51
÷
Avg Total Assets
$136.15B
÷
Avg Stockholders Equity
−$3.06B
Begin Equity
−$183M
End Equity
−$5.93B
Top institutional holders
Q2 2026| Holder | Shares | Chg. shares | |
|---|---|---|---|
| BlackRock, Inc. | 149.5M | -1.2M | $37.62B |
| VANGUARD CAPITAL MANAGEMENT LLC | 115.4M | +515.8K | $29.04B |
| STATE STREET CORP | 82.6M | +1.4M | $20.78B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 48.5M | -1.0M | $12.20B |
| JPMORGAN CHASE & CO | 47.9M | -8.9M | $12.17B |
| GEODE CAPITAL MANAGEMENT, LLC | 47.0M | +260.9K | $11.81B |
| MORGAN STANLEY | 38.9M | +884.2K | $9.79B |
| Capital Research Global Investors | 30.1M | -1.2M | $7.57B |
| NORGES BANK | 25.6M | new | $6.43B |
| BANK OF AMERICA CORP /DE/ | 21.2M | -2.7M | $5.34B |
10 of 4,259
View allTop insider holdings
as reported| Insider | Shares held | |
|---|---|---|
| SALEKI-GERHARDT AZITAOfficer | 201.7K | $57.56M |
| Michael Robert A.Officer | 178.7K | $51.02M |
| FREYMAN THOMAS CDirector | 127.9K | $36.50M |
| Stewart Jeffrey RyanOfficer | 83.2K | $23.74M |
| Donoghoe NicholasOfficer | 74.4K | $21.24M |
| RAPP EDWARD JDirector | 56.4K | $16.08M |
| Thakkar RoopalOfficer | 52.4K | $14.95M |
| TILTON GLENN FDirector | 51.6K | $14.72M |
| AUSTIN ROXANNE SDirector | 39.6K | $11.30M |
| GONZALEZ RICHARD ADirector | — | — |
10 of 25· 1 withheld
View allRecent insider activity
through Aug 14, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| Donoghoe NicholasOfficer | Option Exercise (Rule 16b-3 Exempt) | +32.7K | $2.58M | Aug 14, 2026 |
| Donoghoe NicholasOfficer | Open-Market or Private Sale | -32.7K | $8.18M | Aug 14, 2026 |
| Quaggin Susan EDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| Davis Jennifer L.Director | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| MEYER MELODY BDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| BURNSIDE WILLIAM H.L.Director | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| Hart Brett JDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| Roberts Rebecca BDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| FREYMAN THOMAS CDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
| WADDELL FREDERICK HDirector | Grant/Award (Rule 16b-3(d)) | +1.1K | $0 | May 8, 2026 |
10 of 1,550
View all